Concepedia

B-cell Malignancy Therapy

B-Cell Malignancy Therapy is a therapeutic strategy within hematologic malignancy pharmacotherapy that specifically targets pathological B-cell clones through mechanisms such as monoclonal antibodies, kinase inhibitors, or cellular immunotherapies to induce remission or control disease progression.

1.2K

Publications

89.9K

Citations

9.4K

Authors

2.2K

Institutions

Publications per year

2017–2026

515

Parents

Publications

1.2K

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning et al. · The Lancet · 2020 · 2.3K citations

, , +13

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson et al. · The Lancet Oncology · 2018 · 2.3K citations

, , +12

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Lorenz Trümper, Anders Österborg et al. · The Lancet Oncology · 2006 · 2.1K citations

, , +11

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Frederick L. Locke, David B. Miklos, Caron A. Jacobson et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text

, , +8

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman et al. · Journal of Clinical Oncology · 2012 · 1.1K citations · Full text

, , +17

1–5 of 1.2K

Authors

9.4K

  1. IW
    Ian W. Flinn

    Sarah Cannon, United States

    48 publications · 6.5K citations

    28

    h-index

  2. CS
    Constantine S. Tam

    Peter MacCallum Cancer Centre, Australia

    30 publications · 2.5K citations

    22

    h-index

  3. WG
    William G. Wierda

    The University of Texas MD Anderson Cancer Center, United States

    27 publications · 3.5K citations

    21

    h-index

  4. GS
    Gilles Salles

    Hospices Civils de Lyon, France

    32 publications · 1.9K citations

    20

    h-index

  5. JM
    John M. Pagel

    Fred Hutch Cancer Center, United States

    25 publications · 2.9K citations

    20

    h-index

1–5 of 9.4K

Institutions

2.2K

  1. The University of Texas MD Anderson Cancer Center

    Houston, United States

    48 h-index

    520 publications

    74.7K citations

  2. Dana-Farber Cancer Institute

    Boston, United States

    38 h-index

    291 publications

    45.3K citations

  3. Memorial Sloan Kettering Cancer Center

    New York, United States

    36 h-index

    212 publications

    61.3K citations

  4. Stanford University

    Stanford, United States

    36 h-index

    210 publications

    58.2K citations

  5. National Cancer Institute

    Bethesda, United States

    35 h-index

    208 publications

    24K citations

  6. Cornell University

    Ithaca, United States

    34 h-index

    155 publications

    25K citations

  7. Mayo Clinic in Arizona

    Scottsdale, United States

    33 h-index

    155 publications

    16.4K citations

  8. City Of Hope National Medical Center

    Duarte, United States

    30 h-index

    87 publications

    11.4K citations

1–8 of 2.2K

Venues

  1. Blood

    328 publications · 22.5K citations

    78

    h-index

  2. PubMed

    Repository · 73 publications · 3.6K citations

    33

    h-index

  3. Journal of Clinical Oncology

    66 publications · 6.5K citations

    27

    h-index

  4. Clinical Cancer Research

    32 publications · 2.5K citations

    27

    h-index

  5. British Journal of Haematology

    BJH · 41 publications · 1.8K citations

    25

    h-index

1–5